Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Equities research analysts at HC Wainwright increased their Q1 2025 earnings estimates for RAPT Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.16) per share for the quarter, up from their prior forecast of ($0.63). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.76) EPS.

Separately, Stifel Nicolaus restated a “hold” rating and set a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $5.29.

RAPT Therapeutics Stock Performance

NASDAQ:RAPT opened at $1.25 on Wednesday. The company has a 50-day moving average of $1.22 and a 200-day moving average of $1.53. RAPT Therapeutics has a 52 week low of $0.79 and a 52 week high of $9.65. The company has a market capitalization of $43.70 million, a price-to-earnings ratio of -0.45 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69).

Hedge Funds Weigh In On RAPT Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Picton Mahoney Asset Management boosted its stake in RAPT Therapeutics by 994.4% in the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after purchasing an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares during the last quarter. Readystate Asset Management LP bought a new stake in RAPT Therapeutics during the 3rd quarter worth about $36,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in RAPT Therapeutics in the 4th quarter valued at about $63,000. Finally, Sei Investments Co. bought a new position in shares of RAPT Therapeutics in the fourth quarter worth about $64,000. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.